Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 502

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1C
Chunk 502
---
) 
    $4,055,771 
  
    Balance 
     2,008,689  
    $20  
    $29,489,055  
    $(25,433,304) 
    $4,055,771 

    Common stock issued for reverse stock split fractional share round up 
     115,716  
     1  
     (1) 
     —  
     — 
  
    Common stock issued for conversion of convertible debt accrued interest and principal 
     797,345  
     8  
     1,947,286  
     —  
     1,947,294 
  
    Common stock issued for restricted stock units 
     29,997  
     —  
     —  
     —  
     — 
  
    Issuance of common stock, warrants, and pre-funded warrants, net of issuance fees of $740,477 
     395,574  
     4  
     3,590,406  
     —  
     3,590,410 
  
    Common stock issued for the exercise of pre-funded warrants 
     729,246  
     8  
     722  
     —  
     730 
  
    Stock-based compensation 
     —  
     —  
     259,744  
     —  
     259,744 
  
    Net loss 
     —  
     —  
     —  
     (9,144,797) 
     (9,144,797)
  
    Balance at December 31, 2024 
     4,076,567  
    $41  
    $35,287,212  
    $(34,578,101) 
    $709,152 
  
    Balance at December 31, 2024 
     4,076,567  
    $41  
    $35,287,212  
    $(34,578,101) 
    $709,152 

The
accompanying notes are an integral part of these consolidated financial statements.

F-4

Shuttle
Pharmaceuticals Holdings, Inc.

Consolidated
Statements of Cash Flows

    2024  
    2023 

    Years Ended

    December